Mizuho Begins Coverage on Medline (NASDAQ:MDLN)

Mizuho initiated coverage on shares of Medline (NASDAQ:MDLN) in a research report issued to clients and investors on Monday,Benzinga reports. The firm set an “outperform” rating and a $48.00 price target on the stock. Mizuho’s target price would indicate a potential upside of 18.46% from the company’s previous close.

MDLN has been the subject of a number of other research reports. Royal Bank Of Canada began coverage on Medline in a research report on Monday. They issued an “outperform” rating and a $47.00 price objective for the company. Robert W. Baird initiated coverage on shares of Medline in a research note on Monday. They set an “outperform” rating and a $48.00 price target on the stock. Evercore ISI assumed coverage on shares of Medline in a research report on Monday. They set an “outperform” rating and a $50.00 target price on the stock. Piper Sandler began coverage on shares of Medline in a research report on Monday. They issued an “overweight” rating and a $50.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft started coverage on Medline in a report on Monday. They set a “hold” rating and a $40.00 price objective on the stock. Eighteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $47.25.

Medline Stock Down 1.8%

MDLN opened at $40.52 on Monday. Medline has a 12-month low of $34.89 and a 12-month high of $45.50.

Insider Activity at Medline

In related news, Director Andrew J. Mills bought 2,586,206 shares of the business’s stock in a transaction on Thursday, December 18th. The shares were purchased at an average price of $29.00 per share, with a total value of $74,999,974.00. Following the completion of the purchase, the director owned 2,586,206 shares of the company’s stock, valued at $74,999,974. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Charles N. Mills bought 2,579,310 shares of Medline stock in a transaction on Thursday, December 18th. The shares were bought at an average price of $29.00 per share, for a total transaction of $74,799,990.00. Following the acquisition, the director owned 2,441,379 shares of the company’s stock, valued at approximately $70,799,991. The trade was a -1,870.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies started coverage with a “Buy,” highlighting Medline’s ~$25 billion supply-chain scale as a durable competitive advantage that supports growth and margin expansion. Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
• Positive Sentiment: TipRanks coverage of new sell‑side initiations (e.g., J.P. Morgan) emphasizes Medline’s prime‑vendor position, branded mix shift and margin expansion runway — factors analysts say justify a premium valuation. Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation
• Positive Sentiment: Multiple outlets report a broad set of bullish analyst initiations after the IPO (Buy/Overweight ratings and constructive price targets), which is amplifying positive sentiment and buying interest. Analysts initiate Medline with bullish ratings after blockbuster IPO
• Positive Sentiment: Media and TV coverage — including praise from commentators such as Jim Cramer — is raising retail and institutional visibility for MDLN, supporting near‑term momentum. Jim Cramer Medline: “It’s a Terrific Company”
• Neutral Sentiment: A valuation note points out shares are trading near a DCF estimate after the recent moves, suggesting limited near‑term upside unless execution or margin beats occur — a reminder that much of the positive view is already priced in. Medline (MDLN) Valuation Check As Shares Trade Near DCF Estimate After Recent Moves

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.